Nov2025
Ariana Pharmaceuticals Publishes New Study on AI-Driven Discovery of Genomic Biomarkers for Liver Toxicity Risk
Ariana Pharmaceuticals is proud to announce the publication of a new Real-World Evidence study: “eXp AI-driven Discovery of Genomic Biomarkers for Liver Toxicity Risk – A UK Biobank Case Study.” in The Pharmacogenomics Journal This research showcases how Ariana’s explainable Artificial Intelligence (eXp AI) and proprietary KEM® (Knowledge Extraction & Management) platform can identify genomic […]
Nov2023
ESMO 2023: Advances in the fight against cancer through artificial intelligence.
The collaboration between Ariana Pharma, Omicure, and the Léon Bérard Center has led to a breakthrough in identifying survival biomarkers across various cancer types using eXplainable Artificial Intelligence. In a study, presented at ESMO 2023 [Identification of biomarkers of survival across multiple cancer types using eXplainable Artificial Intelligence], KEM®, a proprietary Ariana Pharma technology, was […]
Jun2022
Ariana Pharma, OmiCure and Centre Léon Bérard (CLB) Comprehensive Cancer Center announce strategic collaboration to implement AI-driven Precision Medicine for cancer patients.
Paris and Cambridge, MA, June 15th 2022. Ariana Pharma and OmiCure announce their collaboration with the renowned CLB Cancer Center to apply OmiCure and Ariana Artificial Intelligence (AI) capabilities to find more efficient treatments for cancer patients. The data were communicated at ASCO 2022 last week and showed that Artificial Intelligence RNA-based therapeutic recommendations have […]